– USA, NC – Revibe Technologies today announced the election of Dr. Mike Ackermann to its Board of Directors effective March 15, 2022., filling the vacancy created by the resignation of Mr. Douglas Brodman.
“Revibe Technologies is excited that Dr. Ackermann has agreed to join our Board of Directors. His accomplished and diverse pharmaceutical background developing and commercializing neuroscience and ADHD products will enable him to provide critical and valuable counsel to our management team,” said Board Chairman, Chris Ng Cashin.
About Dr. Michael Ackermann
Dr. Mike Ackermann is the Co-Founder and CBO at Arrivo Bioventures, a company focusing on early clinical development, and Co-Founder and President of AB Collaborative Investments, an Angel Investment firm, which focuses on local and regional healthcare and IT start-ups. He recently joined Solas Bio Ventures as a Managing Director of Business Development helping Solas build investment portfolios. Previously, Mike worked for several years at Quintiles Transnational as SVP for Global Commercial Solutions, where he developed comprehensive customer solutions to support clients from phase I/II through launch, generating $100 million in net new business. Before Quintiles, Mike spent more than 18 years at Eli Lilly and Company where he served as VP of the US Neuroscience Business Unit. He led the unit’s performance improvement and the launch of Strattera and Cymbalta (Depression). In addition, he held leadership positions in Market Research, Global and US Pricing, Sales, and Global Health Outcomes to support Lilly’s strategic and operational initiatives.
“I am delighted to join the Board of Directors of Revibe Technologies as the company shares my belief that innovative non-pharmacological options need to be available to families as they consider possible ADHD treatment for their children. FokusRx has the potential to help so many people and aligns with my passion of improving the lives of children suffering from ADHD,” commented Dr. Mike Ackermann.
Mike holds a BS degree in biology from Hampden-Sydney College in Virginia, a Ph.D. in immunology from the Drexel University College of Medicine, and an MBA from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill. In addition, he served as the Fogarty International Post-doctoral Fellow at the National Institutes of Health/NIEHS.
About Revibe Technologies
Revibe Technologies is passionate about leveraging technology to help children with focus and attention difficulties, overcome obstacles to succeed in life. Their current product, the Revibe Connect, is a machine-learning wearable that provides personalized vibrations optimized to increase focus and attention in children. FokusRx is an investigational device in development as a potential prescription wearable digital therapeutic for ADHD. FokusRx has not been reviewed by the FDA and is not available for sale.
For more information: https://www.revibetech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.